Gilead, Regeneron, AstraZeneca and more encourage FDA to expand patient reported outcome guidance
More than a half dozen top drugmakers recently called on the FDA to expand its thinking on patient reported outcomes in cancer trials to include …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
